PIK3CA mutation: changing the paradigm of HR+ HER2-negative metastatic breast cancer therapy. Review of the Novartis Pharma satellite symposium, held as part of a virtual forum dedicated to the diagnosis and treatment of patients with hormone-dependent HER2-negative advanced breast cancer with a PIK3CA gene mutation. April 23, 2021

Cover Page

Cite item

Full Text

Abstract

А virtual forum dedicated to the diagnosis and treatment of patients with hormone-dependent HER2-negative advanced breast cancer (HR+ HER2- aBC) with the PIK3CA mutation using target drug alpelisib was held on April 23, 2021. Oncologists from France and Russia discussed the significance of the PIK3CA mutation, the necessity and methods of its identification. They also shared information and exchanged experience of using alpelisib to treat patients who had previously received a CDK4/6 inhibitor and were resistant to endocrine therapy. Using the example of a clinical case, the experts also discussed the issues of prevention and correction of adverse events.

References

  1. Hennessy B, Smith D, Ram P, et al. Exploiting the PI3K/AKT pathway for cancer drug discovery. Nat Rev Drug Discov. 2005;4(12):988-1004. doi: 10.1038/nrd1902
  2. Miller TW, Balko JM, Arteaga CL. Phosphatidylinositol 3-kinase and antiestrogen resistance in breast cancer. J Clin Oncol. 2011;29(33):4452-61. doi: 10.1200/JCO.2010.34.4879
  3. Bosch A, Li Z, Bergamaschi A, et al. PI3K inhibition results in enhanced estrogen receptor function and dependence in hormone receptor-positive breast cancer. Sci Transl Med. 2015;7(283):283ra51. doi: 10.1126/scitranslmed.aaa4442
  4. Janku F, Yap TA, Meric-Bernstam F. Targeting the PI3K pathway in cancer: are we making headway? Nat Rev Clin Oncol. 2018;15(5):273-91. doi: 10.1038/nrclinonc.2018.28
  5. Prat A, Baselga J. The role of hormonal therapy in the management of hormonal-receptor-positive breast cancer with co-expression of HER2. Nat Clin Pract Oncol. 2008;5(9):531-42. doi: 10.1038/ncponc1179
  6. Toska E, Osmanbeyoglu HU, Castel P, et al. PI3K pathway regulates ER-dependent transcription in breast cancer through the epigenetic regulator KMT2D. Science. 2017;355(6331):1324-30. doi: 10.1126/science.aah6893
  7. Vanhaesebroeck B, Guillermet-Guibert J, Graupera M, et al. The emerging mechanisms of isoform-specific PI3K signalling. Nat Rev Mol Cell Biol. 2010;11(5):329-41. doi: 10.1038/nrm2882
  8. Criscitiello C, Marra A, Curigliano G. PIK3CA mutation assessment in HR+/HER2- metastatic breast cancer: overview for oncology clinical practice. J Mol Pathol. 2021;2:42-54. doi: 10.3390/jmp2010005
  9. The Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature. 2012;490(7418):61-70. doi: 10.1038/nature11412
  10. Zardavas D, Te Marvelde L, Milne RL, et al. Tumor PIK3CA genotype and prognosis in early-stage breast cancer: a pooled analysis of individual patient data. J Clin Oncol. 2018;36(10):981-90. doi: 10.1200/JCO.2017.74.8301
  11. Mayer IA, Prat A, Egle D, et al. A phase II randomized study of neoadjuvant letrozole plus alpelisib for hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer (NEO-ORB). Clin Cancer Res. 2019;25(10):2975-87. doi: 10.1158/1078-0432.CCR-18-3160
  12. Bertucci F, Ng CKY, Patsouris A, et al. Genomic characterization of metastatic breast cancers. Nature. 2019;569(7757):560-4. doi: 10.1038/s41586-019-1056-z
  13. Razavi P, Chang MT, Xu G, et al. The Genomic landscape of endocrine-resistant advanced breast cancers. Cancer Cell. 2018;34(3):427-38.e6. doi: 10.1016/j.ccell.2018.08.008
  14. Mosele F, Stefanovska B, Lusque A, et al. Outcome and molecular landscape of patients with PIK3CA-mutated metastatic breast cancer. Ann Oncol. 2020;31(3):377-86. doi: 10.1016/j.annonc.2019.11.006
  15. Baselga J, Im SA, Iwata H, et al. Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2017;18(7):904-16. doi: 10.1016/S1470-2045(17)30376-5
  16. Andre F, Ciruelos E, Rubovszky G, et al. Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer. N Engl J Med. 2019;380:1929-40. doi: 10.1056/NEJMoa1813904
  17. Juric D, Ciruelos E, Rubovszky G, et al. Alpelisib + fulvestrant for advanced breast cancer: Subgroup analyses from the phase III SOLAR-1 trial [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4–8; San Antonio, TX. Philadelphia (PA): AACR. Cancer Res. 2019;79(4 Suppl.):Abstract GS3-08. doi: 10.1158/1538-7445.SABCS18-GS3-08
  18. Rugo H, Mayer I, Conte P, et al. Prevalence of PIK3CA mutations in patients with hormone receptor-positive, human epidermal growth factor-2-negative advanced breast cancer from the SOLAR-1 trial [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29 – Apr 3; Atlanta, GA. Philadelphia (PA): AACR. Cancer Res. 2019;79(13 Suppl.):Abstract CT142.
  19. Mollon L, et al. AACR 2018. Abstract 1207 [poster].
  20. Qin H, Liu L, Sun S, et al. The impact of PI3K inhibitors on breast cancer cell and its tumor microenvironment. PeerJ. 2018;6:e5092. doi: 10.7717/peerj.5092
  21. Ligresti G, Militello L, Steelman LS, et al. PIK3CA mutations in human solid tumors: role in sensitivity to various therapeutic approaches. Cell Cycle. 2009;8(9):352-8. doi: 10.4161/cc.8.9.8255
  22. Samuels Y, Wang Z, Bardelli A, et al. High frequency of mutations of the PIK3CA gene in human cancers. Science. 2004;304(5670):554. doi: 10.1126/science.1096502
  23. Ciruelos EM., Loibl S, Mayer IA, et al. Clinical outcomes of alpelisib plus fulvestrant in hormone receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer with PIK3CA alterations detected in plasma ctDNA by next-generation sequencing: Biomarker analysis from the SOLAR-1 study [abstract]. In: Proceedings of the 2020 San Antonio Breast Cancer Virtual Symposium; 2020 Dec 8–11; San Antonio, TX. Philadelphia (PA): AACR. Cancer Res. 2021;81(4 Suppl.):Abstract PD2-06. doi: 10.1158/1538-7445.SABCS20-PD2-06
  24. Vasan N, Razavi P, Johnson JL, et al. Double PIK3CA mutations in cis increase oncogenicity and sensitivity to PI3Kα inhibitors. Science. 2019;366(6466):714-23. doi: 10.1126/science.aaw9032
  25. Соколова Т.Н., Алексахина С.Н., Янус Г.А., и др. Частота и спектр мутаций PIK3CA при гормонозависимом HER2-отрицательном распространенном раке молочной железы у российских пациенток. Современная Онкология. 2021;23(1):61-7. doi: 10.26442/18151434.2021.1.200744 [Sokolova TN, Aleksakhina SN, Yanus GA, et al. The frequency and spectrum of PIK3CA mutations in patients with estrogen receptor-positive HER2-negative advanced breast cancer residing in various regions of Russia. Journal of Modern Oncology. 2021;23(1):61-7 (in Russian)]. doi: 10.26442/18151434.2021.1.200744
  26. Cardoso F, Senkus E, Costa A, et al. 4th ESO-ESMO International Consensus Guidelines for advanced breast cancer (ABC 4). Ann Oncol. 2018;29(8):1634-57. doi: 10.1093/annonc/mdy192
  27. Rugo HS, Lerebours F, Ciruelos E, et al. Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative study. Lancet Oncol. 2021;22(4):489-98. doi: 10.1016/S1470-2045(21)00034-6
  28. Rugo HS, Lerebours F, Ciruelos E, et al. Alpelisib (ALP) + fulvestrant (FUL) in patients (pts) with PIK3CA-mutated (mut) hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC) previously treated with cyclin-dependent kinase 4/6 inhibitor (CDKi) + aromatase inhibitor (AI): BYLieve study results. Presented at: ASCO20 Virtual Scientific Program. J Clin Oncol. 2020;38(Suppl.):abstr. 1006.
  29. Andre F, Ciruelos E, Rubovszky G, et al. Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer. N Engl J Med. 2019;380:1929-40. doi: 10.1056/NEJMoa1813904
  30. Rugo H, Lerebours F, Juric D, et al. Alpelisib + letrozole in patients with PIK3CA-mutated, hormone-receptor positive (HR+), human epidermal growth factor receptor-2-negative previously treated with a cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) + fulvestrant: BYLieve study results. Abstracts: 2020 San Antonio Breast Cancer Virtual Symposium; December 8-11, 2020; San Antonio, Texas. Poster PD2-07. doi: 10.1158/1538-7445.SABCS20-PD2-07
  31. Juric D, Janku F, Rodón J, et al. Alpelisib plus fulvestrant in PIK3CA-altered and PIK3CA-wild-type estrogen receptor-positive advanced breast cancer: a phase 1b clinical trial. JAMA Oncol. 2019;5(2):e184475. doi: 10.1001/jamaoncol.2018.4475
  32. Andre F et al. Overall survival (os) results from SOLAR-1, a phase III study of alpelisib (ALP) + fulvestrant (FUL) for hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer (ABC). Ann Oncol. 2020;31(Suppl. 4):S1142-215.
  33. Fitzgerald DM, Muzikansky A, Pinto C, et al. 318P. Association between PIK3CA mutation status and development of brain metastases in HR+/HER2- metastatic breast cancer. Ann Oncol. 2019;30(Suppl. 5):v110. doi: 10.1093/annonc/mdz242.013
  34. Batalini F, Moulder SL, Winer EP, et al. Response of brain metastases from PIK3CA-mutant breast cancer to alpelisib. JCO Precis Oncol. 2020;4:PO.19.00403. doi: 10.1200/PO.19.00403
  35. Bergen ES, Berghoff AS, Medjedovic M, et al. Continued endocrine therapy is associated with improved survival in patients with breast cancer brain metastases. Clin Cancer Res. 2019;25(9):2737-44. doi: 10.1158/1078-0432
  36. Arthur LM, Turnbull AK, Renshaw L, et al. Changes in PIK3CA mutation status are not associated with recurrence, metastatic disease or progression in endocrine-treated breast cancer. Breast Cancer Res Treat. 2014;147(1):211-9. doi: 10.1007/s10549-014-3080-x

Copyright (c) 2021 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies